Ionis Subsidiary Akcea Encouraged By Safety Data In FCS
Executive Summary
Phase III data showing statistically significant reduction of triglycerides will bolster the pivotal data expected early next year. Akcea is not concerned by the study’s 20% dropout rate because there were no discontinuations in a subset of patients with FCS.
You may also be interested in...
Akcea Faces Tricky Risk/Benefit Scenario In Orphan Disease FCS
The Ionis subsidiary's volanesorsen shows robust efficacy in a pivotal Phase III trial for familial chylomicronemia syndrome, but with high dropout levels for platelet reduction. Firm says platelet reductions are manageable and stem from the drug working as expected in the rare disease.
Ionis: Another Shot At The Commercial Market And Sustainable Profits
Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.
Isis antisense drug lowers triglycerides; Phase III ongoing
Isis Pharmaceuticals has one Phase III clinical trial under way with a second late-stage trial expected to start before the end of 2015 for its antisense drug volanesorsen (ISIS-APOCIIIRx), which was able to significantly lower patients' triglyceride levels in a Phase II study.